[Several patients with a metastasised gastrointestinal stroma-cell tumor for whom the tide turned by the introduction of imatinib].

摘要: The introduction of imatinib for gastrointestinal stroma-cell tumours (GISTs) reversed the chances 3 cancer patients who had given up hope. One 40-year-old man with multiple chemotherapy-resistant GIST responded well to treatment in a phase-I setting. Another patient, woman aged 77 years, was initially considered too old chemotherapy, but later accepted an phase-III trial due positive results other patients. last 48 also despite massive tumour load and WHO performance status 3. She almost free complaints within period just few weeks. Until recently, prognosis metastatic or irresectable certain death 1 year after diagnosis. recent registration has dramatically changed this disease. These case reports demonstrate that some studies can actually benefit from participation such trials. Furthermore, treating poor condition is justified by high response rates mild toxicity.